Transaction Terms Under the agreement, Royalty Pharma will provide Teva up to $100 million to fund ongoing development costs for olanzapine LAI (TEV-‘749), and Royalty Pharma and Teva have a ...

According to information procured exclusively ahead of a formal announcement Friday, a subsidiary of NYSE-traded giant Teva Pharmaceuticals has signed a deal with medical cannabis company Canndoc ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

FTC opens investigation into Teva, escalating patent fight with pharma industry. Democrats have accused drug companies of “junk patent listings,” arguing that the industry is blocking generic ...

On Tuesday, May 27, an analyst from Truist Securities initiated coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy rating and a price target of $25. Teva Pharma is an ...

Teva has spent the last few years working to resolve its wide-ranging opioid litigation and finally Facing potential $10B trial loss, Teva seeks appeal of recent ruling in kickbacks case Fierce Pharma ...

Israel’s Teva wants in on pharma’s trade association--but its brand-only counterparts aren’t too thrilled with the idea of having a generics giant among their ranks.

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneo ...

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI, a long-acting subcutaneous injectable olanzapine for schizophrenia Phase 3 data expected ...